Do you want to read an article? Please log in or register.
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
Lung Cancer
Related content
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Lung Cancer
10-Year Long-Term Outcomes of Robotic-Assisted Segmentectomy for Early-Stage Non-Small-Cell Lung Cancer
J Clin Med
Casiraghi M, Orlandi R, Mazzella A, Girelli L, Caffarena G, Chiari M, Bertolaccini L, Lo Iacono G, Diotti C, Bardoni C, Maisonneuve P, Spaggiari L
doi: 10.3390/jcm14165608
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
RECOMMENDED
Lung Cancer
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Gemelli M, Sala L, Morabito A, Sforza V, Cortellini A, La Cava G, Bertolini F, Guaitoli G, Carnio S, Novello S, Leonetti A, Tiseo M, Mazzoni F, Cosso F, Macerelli M, Membrino A, Metro G, Chiari R, Genova C, Berardi R, Tassistro E, Antolini L, Cortinovis DL
doi: 10.1016/j.ejca.2026.116579
RECOMMENDED
Lung Cancer
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, Qiao Y, Wang A, Januszewski A
doi: 10.1016/j.cllc.2026.01.005
Lung Cancer
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)
Clin Lung Cancer
Mitome N, Hamada A, Wakabayashi M, Uozumi T, Horinouchi H, Isaka M, Yotsukura M, Aokage K, Fukuda H, Watanabe SI, Tsutani Y, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG)
doi: 10.1016/j.cllc.2026.04.006
Lung Cancer
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study
J Clin Med
Koren E, Yaacov A, Zidan J, C Roisman L, Peled N, Asna N
doi: 10.3390/jcm15124757
Lung Cancer
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Eur J Cancer
Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS
doi: 10.1016/j.ejca.2026.116744
COMMENTED
Lung Cancer
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
JAMA Oncol
Rousseau A, Foulon S, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Aldea M, Parisi C, Gazzah A, Le Pechoux C, Botticella A, Levy A, Simon-Tillaux N, Michiels S, Besse B
doi: 10.1001/jamaoncol.2026.0669